Brind.
  1. Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.
  2. Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.

mRNA Cancer Vaccine Trial Reduces Melanoma Recurrence Risk by 42%

1 report, 1 independent Updated Oct 22
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

An Australian-led Phase 3 trial, funded by Merck and Moderna, found that adding a personalized mRNA cancer vaccine reduced the risk of melanoma recurrence or death by 42% compared to patients receiving only the immunotherapy drug, pembrolizumab (Keytruda). The trial involved 1137 participants who had previously undergone surgery for melanoma. Two-thirds of the participants received the mRNA therapeutic vaccine, while the remainder received a placebo injection.

From theage.com.au

Why it matters

Some supportBrind's analysis of the reports

The results signal a major advancement in personalized cancer medicine. The trial supports the joint work between Moderna and Merck on combination therapies. This success could accelerate the regulatory review process for the combined therapy by the FDA.

Moderna and Merck are seeking FDA review for a novel cancer treatment after co-leading a Phase 3 mRNA vaccine trial. They are also developing cancer vaccines in partnership, and Moderna is pursuing approval for its seasonal influenza vaccine.

From theage.com.au

Who's involved

  • University of SydneyThe University of Sydney affiliated with the Melanoma Institute Australia where the trial was conducted
  • MerckCo-funded the trial and supplies the immunotherapy drug, pembrolizumab
  • ModernaCo-funded the trial and designed the personalized mRNA therapeutic vaccine

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

How it developed

Newest first. Tap a step to see who reported it.
  1. Moderna's therapy combined with Merck's drug in an Australian-led clinical trial.Sub-event
  2. The novel cancer treatment trial co-led by Moderna and Merck is being conducted in Australia.1 source

Keep exploring

Part of

Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial. All 2 developments

Within Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.

The entities involved

Coverage

Newest first; wire copies grouped